Cinclus Pharma Holding AB (publ) (Cinclus Pharma) is a Sweden-based research based biotech company developing small molecules for the treatment of gastric acid related diseases. The Company is developing linaprazan glurate, which is being developed for the treatment of severe gastroesophageal reflux disease (GERD). The Company's mission is to introduce products impacting standard of care for patients with gastric acid related diseases, underpinned by the superior P-CAB linaprazan glurate. Cinclus Pharma is in an intensive development phase, ramping up the organization and company structure to prepare for growth and the further development of linaprazan glurate. Cinclus Pharma owns the worldwide commercial rights for linaprazan glurate. Secured commercial rights are central in utilizing the process of launching the product in markets worldwide.